To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients

Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients

Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients.

Study Overview

• Status: Completed
• Conditions: Migraine
• Intervention / Treatment: Drug: PACAP-38 Challenge Agent; Drug: Placebo; Drug: Erenumab

• Study Type: Interventional
• Enrollment (Actual): 35
• Phase: Phase 1

Contacts and Locations

Study Locations

• Belgium
  • Leuven, Belgium, 3000
    • Research Site
• Netherlands
  • Leiden, Netherlands, 2333 CL
    • Research Site
• United States
  • California
    • Anaheim, California, United States, 92801
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Adults ≥ 18 to ≤ 45 years of age upon entry into screening
• History of migraine headaches without aura for ≥ 6 months prior to screening according to the International Headache Society (IHS) International Classification of Headache Disorders (ICHD-II) (Headache Classification Committee of the International Headache Society, 2004) based on medical records and/or patient self-report
• Migraine frequency: ≥ 1 and ≤ 5 migraine days per month in each of the 3 months prior to screening

Exclusion Criteria:

• History of migraine with aura, cluster headache or hemiplegic migraine headache according to the IHS Classification ICHD-II (Headache Classification Committee of the International Headache Society, 2004) based on medical records and/or patient self-report
• ≥ 6 migraine days per month in the last 3 months prior to study enrollment and during screening period
• Other headache disorders (except for episodic tension-type headache <5 days/month)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: PACAP-38 Challenge Agent; In Part A, 4 cohorts of 2 to 5 participants sequentially received an intravenous infusion of 10 picomol/kilogram/minute (pmol/kg/minute) PACAP-38 for 2.5, 5, 7.5 and 10 minutes each in order to determine the dose for Part B.	Drug: PACAP-38 Challenge Agent; Administered by intravenous infusion during Part A of the study for dose selection for Part B. Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack.; Other Names: Pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38)
Placebo Comparator: Placebo; Participants were randomized to receive matching erenumab placebo by intravenous administration over 30 minutes on day 1. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.	Drug: PACAP-38 Challenge Agent; Administered by intravenous infusion during Part A of the study for dose selection for Part B. Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack.; Other Names: Pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38); Drug: Placebo; Administered once on day 1 of Part B of the study by intravenous infusion.
Experimental: Erenumab; Participants were randomized to receive 140 milligrams (mg) erenumab by intravenous administration over 30 minutes on day 1 in Part B. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.	Drug: PACAP-38 Challenge Agent; Administered by intravenous infusion during Part A of the study for dose selection for Part B. Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack.; Other Names: Pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38); Drug: Erenumab; Administered once on day 1 of Part B of the study by intravenous infusion.; Other Names: AMG 334; Aimovig™

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With a MLA Within 24 Hours of Challenge Agent Infusion	On day 1 of the double-blind randomization phase participants received 140 mg intravenous erenumab over 30 minutes or matching placebo. On day 8, participants received 10 mol/kg/minute PACAP-38 over 10 minutes and were observed for 24 hours after PACAP-38 infusion. A MLA was defined as fulfilling 1 of the 2 criteria: Headache with at least 2 of the following characteristics: unilateral location, pulsating quality, moderate or severe pain intensity, aggravated by/causing avoidance of routine physical activity. Additionally, during the headache at least 1 of the following: nausea and/or vomiting, photophobia or phonophobia.; Headache described as mimicking usual migraine attack treated with triptan.	Part B randomization phase day 8 plus 24 hours.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With a Headache Within 24 Hours of Challenge Agent Infusion	On day 1 of the double-blind randomization phase participants received 140 mg intravenous erenumab over 30 minutes or matching placebo. On day 8, participants received 10 mol/kg/minute PACAP-38 over 10 minutes and were observed for 24 hours after PACAP-38 infusion.	Part B randomization phase day 8 plus 24 hours.
Number of Participants With Treatment Emergent Adverse Events (TEAEs)	TEAEs were summarised for days 1 to 7 after the participants received placebo or erenumab infusion on day 1 of the Part B randomization phase. TEAEs were also summarized from day 8 to end of study (EOS) after participants had received both investigational product (placebo or erenumab) and the second dose of PACAP-38 on day 8.	Part B randomization phase day 1 until EOS (up to 12 weeks).
Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Day 1, Day 8 and EOS	Systolic and diastolic BP was assessed during Part B of the study, and the mean change from baseline is presented for the last measurements taken following administration of placebo or erenumab on day 1 (1 hour post-dose), and following administration of PACAP-38 on day 8 (8 hours post-dose). The mean change from baseline is also presented for the EOS assessment.	Part B randomization phase baseline and day 1, day 8 and EOS (week 12).
Mean Change From Baseline in Heart Rate at Day 1, Day 8 and EOS	Heart rate was assessed during Part B of the study, and the mean change from baseline is presented for the last measurements taken following administration of placebo or erenumab on day 1 (1 hour post-dose), and following administration of PACAP-38 on day 8 (8 hours post-dose). The mean change from baseline is also presented for the EOS assessment.	Part B randomization phase baseline and day 1, day 8 and EOS (week 12).
Mean Change From Baseline in Respiratory Rate at Day 1, Day 8 and EOS	Respiratory rate was assessed during Part B of the study, and the mean change from baseline is presented for the last measurements taken following administration of placebo or erenumab on day 1 (1 hour post-dose), and following administration of PACAP-38 on day 8 (8 hours post-dose). The mean change from baseline is also presented for the EOS assessment.	Part B randomization phase baseline and day 1, day 8 and EOS (week 12).
Mean Change From Baseline in Temperature at Day 1, Day 8 and EOS	Temperature was assessed during Part B of the study, and the mean change from baseline is presented for the last measurements taken following administration of placebo or erenumab on day 1 (1 hour post-dose), and following administration of PACAP-38 on day 8 (8 hours post-dose). The mean change from baseline is also presented for the EOS assessment.	Part B randomization phase baseline and day 1, day 8 and EOS (week 12).
Mean Change From Baseline in Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) at Day 8, Day 9 and EOS	ALP, ALT and AST were assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.	Part B randomization phase baseline and day 8, day 9 and EOS (week 12).
Mean Change From Baseline in Total Bilirubin at Day 8, Day 9 and EOS	Total bilirubin was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.	Part B randomization baseline and day 8, day 9 and EOS (week 12).
Mean Change From Baseline in Blood Urea at Day 8, Day 9 and EOS	Blood urea was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.	Part B randomization baseline and day 8, day 9 and EOS (week 12).
Mean Change From Baseline in Creatine Kinase at Day 8, Day 9 and EOS	Creatine Kinase was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.	Part B randomization baseline and day 8, day 9 and EOS (week 12).
Mean Change From Baseline in Creatinine at Day 8, Day 9 and EOS	Creatinine was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.	Part B randomization baseline and day 8, day 9 and EOS (week 12).
Mean Change From Baseline in Direct Bilirubin at Day 8, Day 9 and EOS	Direct bilirubin was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.	Part B randomization baseline and day 8, day 9 and EOS (week 12).
Mean Change From Baseline in Eosinophil Count at Day 8, Day 9 and EOS	Eosinophil count was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.	Part B randomization baseline and day 8, day 9 and EOS (week 12).
Mean Change From Baseline in Blood Glucose at Day 8, Day 9 and EOS	Blood glucose was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.	Part B randomization baseline and day 8, day 9 and EOS (week 12).
Mean Change From Baseline in Hemoglobin A1C (Fraction of 1) at Day 8, Day 9 and EOS	Hemoglobin A1C was assessed during Part B of the study, and the mean change from baseline is presented for samples taken prior to administration of PACAP-38 on day 8 (pre-PACAP-38 dose), and following administration of PACAP-38 on day 9. The mean change from baseline is also presented for the EOS assessment.	Part B randomization baseline and day 8, day 9 and EOS (week 12).
Pharmacokinetics (PK): Mean Erenumab Serum Concentration at 1 Hour (C1h)	The mean serum erenumab concentration at 1 hour post-dose on day 1 of Part B randomization phase is presented.	Part B randomization phase 1 hour post-dose day 1.
PK: Mean Area Under the Concentration-time Curve From Time 0 to 84 Days Post-dose (AUC84d)	The mean AUC84d for erenumab for the Part B randomization phase is presented.	Part B randomization phase baseline and 84 days post-dose.
Number of Participants With Anti-Erenumab Antibodies	Participants were tested for binding antibodies and neutralizing antibodies at baseline and following treatment with erenumab.	Part B randomization phase baseline and EOS.
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters	At baseline, 12-lead ECGs were performed in a standardized method, in triplicate, and approximately 30 seconds apart, prior to blood draws or other invasive procedures. Single ECGs were performed from Day 1 to EOS. ECG results were reviewed by the investigator and classified as: normal, abnormal not clinically significant or abnormal, clinically significant. The number of participants with abnormal, clinically significant changes in ECG results at EOS are presented.	Part B randomization phase baseline and EOS.
Number of Participants With Clinically Significant Changes in Physical Parameters	Physical examinations were performed by an investigator and any abnormal findings, judged to be clinically significant were recorded as an AE. The number of participants with clinically significant changes in physical parameters at EOS are presented.	Part B randomization phase baseline and EOS.
Number of Participants With Clinically Significant Changes in Neurological Assessments	Neurological examinations including assessment of cranial nerves, motor system, sensory system (including testing for pain sensation [pin prick], light touch sensation [brush], von Frey, and vibratory sense), reflexes, and cerebellar function were performed by the investigator and classified as normal or abnormal. Any abnormal findings, judged by the investigator to be clinically significant, were recorded as an AE. The number of participants with clinically significant changes in neurological assessments at EOS are presented.	Part B randomization phase baseline and EOS.

Collaborators and Investigators

• Sponsor: Amgen

Publications and helpful links

Helpful Links

• AmgenTrials clinical trials website

Study record dates

Study Major Dates

• Study Start (Actual): November 11, 2015
• Primary Completion (Actual): September 28, 2017
• Study Completion (Actual): November 8, 2017

Study Registration Dates

• First Submitted: September 3, 2015
• First Submitted That Met QC Criteria: September 3, 2015
• First Posted (Estimate): September 7, 2015

Study Record Updates

• Last Update Posted (Actual): June 3, 2019
• Last Update Submitted That Met QC Criteria: February 27, 2019
• Last Verified: February 1, 2019

More Information

Terms related to this study

• Keywords: Migraine; Headache; Amgen; Migraine Headache; Headache, Migraine
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Headache Disorders, Primary; Headache Disorders; Migraine Disorders; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Vasodilator Agents; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Growth Substances; Calcitonin Gene-Related Peptide Receptor Antagonists; Erenumab; Pituitary Adenylate Cyclase-Activating Polypeptide
• Other Study ID Numbers: 20140207